CNS Pharmaceuticals raises $22.5M to pursue oncology and neurology acquisitions.

CNS Pharmaceuticals secured a $22.5 million financing round to support a strategic pivot toward high-value oncology and neurology development. This capital injection validates the company's operational strategy and facilitates the acquisition of differentiated clinical-stage assets.